适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- Hifibio Inc.
- 入组人数
- 376
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
A Study of HFB301001 in Adult Patients With Advanced Solid TumorsAdvanced cancer of different organsMedDRA version: 21.1Level: LLTClassification code: 10065252Term: Solid tumor Class: 10029104CTIS2023-506402-39-00Hifibio Inc.170
进行中（未招募）
1 期
A First-in-Human Study to Evaluate the Safety and Anti-cancer Activity of the product FS222, which is an Antibody medication, in Subjects with Advanced MalignanciesAdvanced MalignanciesMedDRA version: 21.0Level: LLTClassification code: 10048683Term: Advanced cancer Class: 10029104CTIS2024-514010-12-00Invox Pharma Limited131
进行中（未招募）
1 期
A Phase I, open-label, randomized, two period, cross-over study in healthy subjects to assess the bioavailability of different formulations of deucrictibant administered as single dose under fasting condition.Hereditary angioedema (HAE)MedDRA version: 23.1Level: PTClassification code: 10019860Term: Hereditary angioedema Class: 100000004850CTIS2024-511196-15-00Pharvaris Netherlands B.V.14
招募中
1 期
Dose escalation trial of BNT152+153 in patients with cancerVarious solid tumors that are metastatic or unresectableMedDRA version: 20.0Level: LLTClassification code: 10025648Term: Malignant mast cell tumors unspecified site extranodal and solid organ sites Class: 10029104CTIS2023-509508-13-00BioNTech SE4
招募中
1 期
A Study of NB003 in Patients With Advanced MalignanciesCTIS2022-502401-15-00ingbo Newbay Technology Development Co. Ltd.290